O1385
Ozagrel hydrochloride hydrate
≥98% (HPLC), solid
Synonym(s):
(E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride hydrate, OKY-046
Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C13H12N2O2 · HCl · xH2O
CAS Number:
Molecular Weight:
264.71 (anhydrous basis)
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Quality Level
Assay
≥98% (HPLC)
form
solid
storage condition
desiccated
color
white to off-white
solubility
H2O: soluble
storage temp.
room temp
SMILES string
O.Cl.OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1
InChI
1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;
InChI key
OWIZTYOMGVTSDP-TXOOBNKBSA-N
Related Categories
Application
Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:
- in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction
- to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes
- to test its effect on arteriolar vasoconstriction in hyperglycemic mice
Biochem/physiol Actions
Ozagrel is a selective thromboxane A2 synthase (TXA2) inhibitor.
Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation. Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia. It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).
Storage Class Code
11 - Combustible Solids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yoshio Suzuki et al.
Neurologia medico-chirurgica, 48(6), 241-247 (2008-06-25)
Sub-analysis of the fasudil post-marketing surveillance study compared the safety and efficacy of fasudil plus ozagrel to fasudil only. A total of 3690 patients received fasudil and 1138 received fasudil plus ozagrel between 1995 and 2000. The occurrence of adverse
Akihiro Koumura et al.
The Journal of pharmacology and experimental therapeutics, 338(1), 337-344 (2011-04-16)
Rho kinase (ROCK), one of the serine/threonine kinases, is involved in pathologic conditions, and its activation causes neuronal cell death. Fasudil, a selective ROCK inhibitor, has been reported to cause increased cerebral blood flow (CBF) in the ischemic brain and
Min-ho Kim et al.
Microvascular research, 73(2), 150-155 (2006-12-13)
This study addresses the role of venule-derived mediators in the arteriolar constriction that accompanies hypercholesterolemia. Constriction was assessed by measuring the tone of small arterioles closely paired with venules in the mesentery of normal cholesterol rats (NC), high cholesterol rats
Seungjun Lee et al.
Microcirculation (New York, N.Y. : 1994), 15(5), 379-387 (2008-06-25)
Reductions in retinal blood flow are observed early in diabetes. Venules may influence arteriolar constriction and flow; therefore, we hypothesized that diabetes would induce the constriction of arterioles that are in close proximity to venules, with the constriction mediated by
Yukiko Enomoto et al.
Atherosclerosis, 209(2), 415-421 (2009-11-26)
The plasma level of soluble CD40 ligand (sCD40L), which induces pro-inflammatory and pro-atherogenic responses, is known to be elevated in atherosclerotic patients. In this study, we investigated the mechanism of sCD40L release from human platelets, focusing on the involvement of
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service